Are you Dr. Coyle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 67 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
375 Dixmyth Ave
Cincinnati, OH 45220Phone+1 513-853-1300Fax+1 513-451-1356
Summary
- Dr. Thomas Coyle, MD is an oncologist in Cincinnati, Ohio. He is currently licensed to practice medicine in Ohio, Florida, and New York. He is affiliated with Good Samaritan Hospital, Select Specialty Hospital-Cincinnati, and Bethesda North Hospital.
Education & Training
SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1988 - 1989
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1985 - 1987- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1982 - 1985
SUNY Upstate Medical UniversityClass of 1982
Certifications & Licensure
NY State Medical License 1983 - Present
OH State Medical License 2015 - 2023
FL State Medical License 1996 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2007
Clinical Trials
- Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- 69 citationsRituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.Sushama Jasti, Thomas Coyle, Teresa Gentile, Lawrence Rosales, Bernard J. Poiesz
Journal of Clinical Apheresis. 2008-01-01 - 100 citationsGossypol treatment of recurrent adult malignant gliomas.Peter Bushunow, Marcus M. Reidenberg, John J. Wasenko, Jeffrey A. Winfield, Beverly J. Lorenzo
Journal of Neuro-Oncology. 1999-05-01 - 37 citationsPhase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastomaDavid Schiff, Santosh Kesari, John de Groot, Tom Mikkelsen, Jan Drappatz
Investigational New Drugs. 2015-02-01
Professional Memberships
- Member
- Fellow
